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Background. N-terminal probrain natriuretic peptide (NT-proBNP) is a hormone involved in the regulation of cardiovascular
homeostasis. Changes in serumNT-proBNP during large volume paracentesis (LVP) in patients with ascites have never before been
examined. Aims. To determine if significant changes in serum NT-proBNP occur in patients undergoing LVP and the associated
clinical correlates in patients with cirrhosis. Method. A total of 45 patients with ascites were prospectively recruited. Serum NT-
proBNP, biochemistry, and haemodynamics were determined at baseline and at key time points during and after paracentesis.
Results. 34 patients were analysed; 19 had ascites due to cirrhosis and 15 from malignancy. In those with cirrhosis, NT-proBNP
decreased by 77.3 pg/mL at 2 L of drainage and 94.3 pg/mL at the end of paracentesis, compared with an increase of 10.5 pg/mL
and 77.2 pg/mL in cancer patients at the same time points (𝑃 = 0.05 and 𝑃 = 0.03). Only congestive cardiac failure (CCF) was
an independent predictor of significant NT-proBNP changes at the end of drainage in cirrhotic patients (𝑃 < 0.01). There were
no significant changes in haemodynamics or renal biochemistry for either group. Conclusion. Significant reductions in serum NT-
proBNP during LVP occur in patients with cirrhosis but notmalignancy, and only comorbid CCF appeared to predict such changes.
1. Introduction
Ascites is the most common cause of hospital admissions
in cirrhotic patients. The development of ascites predicts a
mortality of approximately 15% and 44% at one and five years,
respectively [1]. Total therapeutic large volume paracentesis
(LVP) has been shown to be a safe means of treating tense
or refractory ascites [2, 3]. Postparacentesis circulatory dys-
function (PCD) describes the development of neurohumoral
changes and circulatory disturbances which can arise follow-
ing fluid shifts induced by LVP in patients with cirrhosis.This
syndrome has been associated with a significant increase in
intrahepatic vascular resistance, higher rates of ascites recur-
rence, the development of hepatorenal syndrome, dilutional
hyponatraemia, and decreased overall survival [4, 5]. Sup-
plementation with plasma expanders during paracentesis,
particularly albumin, can reduce this risk [6, 7]; however, it
still occurs in 16–27% of patients [8, 9]. Currently there are no
well-defined risk factors that can reliably identify the subset
of patients who are at greatest risk of PCD.
Brain natriuretic peptide (BNP) is a hormone produced
by the cardiac ventricles which is involved in the regulation
of fluid volumes and cardiovascular homeostasis. Elevations
in plasma BNP reflect fluid overload, while reductions in
BNP reflect relative intravascular depletion. Plasma BNP is
increased in a number of disease states including congestive
cardiac failure (CCF), chronic renal failure (CRF), hyperten-
sion (HT), and cirrhosis [10]. Serum BNP levels have been
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shown to correlate with more advanced cirrhosis and have
been shown to independently predict shorter survival in the
pre- and posttransplant setting [11–13]. It is also thought to be
a usefulmarker for the diagnosis of insidious cardiac dysfunc-
tion in cirrhotic patients [11, 12]. N-terminal- (NT-) proBNP
is the prohormone of BNPwith amore stable and longer half-
life which allows for more reliable assessment of associated
changes. Dynamic changes in serumNT-proBNP in cirrhotic
patients undergoing LVP have never before been examined.
The primary aim of the current study was to determine
whether significant changes in serum NT-proBNP occur
in patients with ascites secondary to cirrhosis undergoing
LVP in comparison to patients with noncirrhotic ascites. We
further sought to determine if changes in serumNT-proBNP
during LVP correlate with alterations in haemodynamics
or serum biochemistry and whether colloid administration
could prevent these changes.We hypothesised that significant
serum NT-proBNP changes would occur in the cirrhotic but
not the malignant cohort.
2. Materials and Methods
FromDecember 2011 to November 2012, consecutive patients
with ascites requiring therapeutic paracenteses were prospec-
tively recruited from the South Western Area Health Service
at Westmead Public Hospital in Sydney, Australia. Both
inpatients and outpatients were included. The study was
approved by the hospital ethics committee in accordancewith
the Helsinki Declaration of 1975, and written and informed
consent was obtained from all participants.
Patients were included if their age was greater than
18 years, the treating physician had deemed a therapeutic
paracentesis as an appropriate and safe treatment for the
management of ascites, and the patient had not suffered any
prior complications from an ascitic drainage which required
hospital admission. Participants in the cirrhosis cohort were
confirmed either clinically or with biopsy, while those in
the malignancy cohort had diagnoses of cancer confirmed
either histologically or cytologically. Patients were excluded
if they had evidence of concurrent cirrhosis and malignancy
(excluding hepatocellular carcinoma) and if any medical or
psychiatric illnesses precluded the acquisition of informed
consent.
Information on the underlying cause of cirrhosis or type
of malignancy, medical comorbidities, other complications
of portal hypertension in the cirrhotic patients (namely,
varices, previous spontaneous bacterial peritonitis, or hepatic
encephalopathy) and the use of diuretics were recorded at
recruitment.
All patients underwent paracentesis using a 16-gauge
plastic cannula which was inserted under aseptic technique
into the lower abdominal cavity. Each cannulawas attached to
a collection set with drainage into volume-graduated bags.
Drainage was continued until no further abdominal fluid
could be collected. All patients underwent measurements
of heart rate, blood pressure, serum biochemistry, and NT-
proBNP at baseline, at 2 litres (L) of drainage, and at the end
of drainage. In the group with ascites secondary to cirrhosis
100mls of 20% albumin (Albumex 20) was also administered
for every 2 L of fluid drained, and serum NT-proBNP was
measured at thirtyminutes following albumin administration
after 2 L of drainage. Only patients who drained >3 L of
ascitic fluid were considered to have had LVP. A subset of
the cirrhotic cohort also had serumbiochemistry and haemo-
dynamics remeasured at 5–7 days following paracentesis to
examine delayed changes with LVP.
Serum NT-proBNP measurements were made using a
two-site (sandwich complex) immunoassay (Elecsys proBNP
II, Roche Diagnostics GmbH, Mannheim, Germany) with a
cutoff value ≥125 pg/mL considered as abnormal. Biochem-
ical analyses for protein, albumin, lactate dehydrogenase
(LDH), and differential cell counts were also undertaken on
the ascitic fluid collected in each patient.
Statistical analysis was performed using SPSS software
(SPSS version 16.0, Chicago, IL, USA). Changes in BNP were
assessed by t-tests and nonparametric correlation, and two-
tailed 𝑃 values of ≤0.05 were regarded as significant through-
out. Multivariate analysis on clinical correlates was assessed
using backward stepwise regression.
3. Results
3.1. Baseline Characteristics. A total of 45 patients were
recruited during the study period. Of these, only 34 patients
who drained >3 L of fluid were included for analysis. Nine-
teen had ascites secondary to cirrhosis, and fifteen had ascites
secondary to malignancy. The patients in each group were
similar with respect to age and gender (Table 1). The most
common cause of cirrhosis was alcohol (7/19 [37%]), while
the commonest cause ofmalignancywas gynaecological (7/15
[47%]). All cirrhotic patients had either Child-Pugh B or C
disease, and the median MELD score was 16.
As expected, patients with cirrhosis had a significantly
higher serum bilirubin (58.2 𝜇mol/L versus 11.6 𝜇mol/L, 𝑃 =
0.03), INR (1.56 versus 1.05, 𝑃 < 0.01) and serum albumin
to ascitic gradient (18 versus 15, 𝑃 = 0.03) but lower platelet
counts (125 × 109/L versus 463 × 109/L, 𝑃 < 0.01) and ascitic
fluid protein (25 g/L versus 34 g/L, 𝑃 = 0.02). Cirrhotic
patients were also more likely to be on diuretics (12/19 (63%)
versus 2/15 (13%),𝑃 < 0.01) and had slower resting heart rates
(79 versus 93 beats per minute, 𝑃 = 0.02).
A greater number of cirrhotic patients had concurrent
CCF/CRF/HT (12/19 (63%) versus 3/15 (20%), 𝑃 = 0.01),
but when CCF was considered alone, this was not statistically
significant (6/19 (32%) versus 1/15 (7%), 𝑃 = 0.06). Mean
serumNT-proBNP was not statistically different between the
two groups (1191.3 pg/mL in cirrhotics versus 567.3 pg/mL in
malignancy,𝑃 = 0.16); however, in the cirrhotic cohort, those
with concurrent CCF/CRF/HT had significantly higher base-
line NT-proBNP levels (1724.2 pg/mL versus 277.7 pg/mL,
𝑃 = 0.03).
3.2. Changes in Serum NT-proBNP. Serum NT-proBNP lev-
els decreased by 77.3 pg/mL at 2 L of drainage (prealbumin
administration) in those with cirrhosis compared to an
increase of 10.47 pg/mL in the patients with malignancy (𝑃 =
0.05, 95% CI: −173.7–−1.7). Similarly, at the end of drainage
NT-proBNP decreased by 94.3 pg/mL in the cirrhotics versus
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Table 1: Baseline characteristics for patients with cirrhosis and malignancy.
Baseline characteristic Cirrhosis (𝑛 = 19) Malignancy (𝑛 = 15) 𝑃 value
Age (years) 59 (12.3) 62 (17.2) 0.62
Male gender 13 (68.4%) 7 (46.7%) 0.30
Primary cause of ascites
Etoh: 7 (37%), viral: 3 (15.8%), etoh + viral: 4
(21.1%), NASH: 4 (15.8), and other: 2
(10.6%).
Gynae: 7 (47%), GI: 3 (20%), and
other: 5 (33%) —
Child-Pugh score B: 11 (58%), C: 8 (42%) — —
MELD score 16 (7) — —
Comorbid CCF/CRF/HT 12 (63%) 3 (20%) 0.01
Comorbid CCF 6 (32%) 1 (7%) 0.06
Diuretics 12 (65.2%) 2 (13.3%) <0.01
Serum NT-proBNP (pg/mL) 1191.3 (1748.8) 567.3 (638.1) 0.16
Serum Na (mmol/L) 136 (4.7) 136 (5) 0.78
Serum creatinine (𝜇mol/L) 102.6 (45.4) 77.0 (28.2) 0.05
eGFR (mL/min) 64.6 (24.1) 76.7 (15.6) 0.09
Serum bilirubin (𝜇mol/L) 58.2 (85.3) 11.6 (10.4) 0.03
Serum albumin (g/L) 30.4 (5.3) 31.7 (4.7) 0.44
ALT (U/L) 37.0 (25.5) 24.2 (23.3) 0.14
AST (U/L) 72.6 (41.2) 46.6 (32.9) 0.06
GGT (U/L) 116. 6 (92.0) 116. 7 (190.7) 1.00
ALP (U/L) 158.0 (107.1) 155.5 (128.2) 0.95
INR 1.56 (0.5) 1.05 (0.1) <0.01
Haemoglobin (g/L) 108.9 (20.4) 117.7 (20.7) 0.23
White cell count (×109/L) 6.2 (3.7) 8.9 (4.6) 0.07
Platelet count (×109/L) 124.9 (66.0) 463.2 (193.3) <0.01
SAAG 18.3 (4.4) 14.9 (4.1) 0.03
Ascitic fluid protein (g/L) 24.9 (8.0) 34.3 (12.9) 0.02
Heart rate (beats/min) 79.3 (14.7) 92.5 (15.3) 0.02
Systolic blood pressure (mmHg) 114.7 (14.9) 124.8 (14.7) 0.06
Diastolic blood pressure (mmHg) 74.8 (19.0) 76.1 (7.0) 0.81
Total volume drained (Litres) 5.6 (2.1) 5.0 (1.9) 0.43
∗All continuous variables have been expressed as a mean (SEM).
∗∗Renal failure is defined as eGFR < 60mL/min.
MELD: model for end-stage liver disease; CCF: congestive cardiac failure; CRF: chronic renal failure; HT: hypertension; Na: sodium; eGFR: estimated
glomerular filtration rate; ALT: alanine aminotransferase; AST: aspartate aminotransferase; GGT: gamma glutamate transferase; ALP: alkaline phosphatase;
INR: international normalised ratio; SAAG: serum ascites albumin gradient.
an increase of 77.2 pg/mL in themalignancy cohort (𝑃 = 0.03,
95% CI: −323.1–−19.7) (Figure 1). The changes in serum NT-
proBNP levels for the cirrhotic cohort at 2 L of drainage and
at the end of drainage in comparison to baseline were both
significant (𝑃 = 0.02 and 𝑃 = 0.05, resp.).
3.3. Clinical Correlates. In the cirrhotic cohort, change in
serum NT-proBNP at the end of drainage was significantly
associated with comorbid CCF but not CRF or HT (mean
decline of 272.5 pg/mL versus 5.17 pg/mL, 𝑃 = 0.04). Higher
MELD scores also correlated with significant NT-proBNP
changes at the end of drainage but failed to reach statistical
significance at 2 L of drainage (𝑃 = 0.05 and 𝑃 = 0.06,
resp.). Conversely, baseline GGT and SAAG appeared to have
significant association at 2 L of drainage but not at the end of
drainage. On multivariate analysis, only CCF was a predictor
of significant NT-proBNP changes at the end of drainage
(𝑃 < 0.01).
The aeitology of liver disease and Child-Pugh score
were not significant and neither was a history of gastrooe-
sophageal varices, spontaneous bacterial peritonitis, or hep-
atic encephalopathy. Current diuretic therapy and the total
volume drained also appeared to be unimportant (Table 2).
Changes in haemodynamics and serum biochemistry did
not significantly correlate with any changes in serum NT-
proBNP at either time point nor were any significant delayed
changes seen in the subgroup of patients (𝑛 = 6) who had
these measurements repeated at 5–7 days from paracentesis.
3.4. Changes with Colloid Administration. Serum NT-
proBNP levels did not significantly change from 2 L of ascites
removal to the end of drainage (mean decline of 17 pg/mL,
𝑃 = 0.67). This corresponded with the administration of
185mls of concentrated albumin for a mean 3.7 L of addi-
tional fluid removed. Similarly, in the subset of patients with





































Figure 1: Mean changes in NT-proBNP levels during key LVP time
points in each group. Mean NT-proBNP change at 2 L prealbumin
−77.3 pg/mL in cirrhotics versus +10.47 pg/mL in cancer patients
(𝑃 = 0.05) and −94.3 pg/mL versus +77.2 pg/mL at the end of drain-
age (𝑃 = 0.03). 95% confidence interval −173.7–−1.7 and −323.1–
−19.7 in cirrhotics for both time points, respectively.
not significantly altered from 2 L of drainage to the end
of paracentesis (mean decline of 41.7 pg/mL, 𝑃 = 0.32),
corresponding to a mean additional drainage of 4.1 L with
205mls of supplemental albumin (Table 3).
4. Discussion
To our knowledge, this is the first study examining dynamic
changes in serum NT-proBNP levels during large volume
paracentesis (LVP). Our results indicate that (i) significant
serum NT-proBNP changes occur during LVP in patients
with cirrhosis but not malignancy, (ii) cirrhotic patients with
CCF show greatest reductions in serumNT-proBNP andmay
therefore be at greatest risk of haemodynamic complications
following LVP, and (iii) albumin supplementation appears to
ameliorate the intravascular depletion associated with LVP.
As anticipated, significant NT-proBNP reductions were
not seen in the malignant cohort during LVP as the patho-
genetic mechanisms leading to ascites in these patients are
thought to relate to lymphatic obstruction and increased
capillary permeability rather than cardiovascular dysfunction
[14]. Results from three patients with concurrent cirrhosis
and limited HCC were included in the analysis, with their
serum NT-proBNP changes not significantly different from
those seen among cirrhotic patients without HCC. Despite
the greater number of patients with concurrent CCF/CRF/
HT in the cirrhotic cohort, when CCF was considered alone,
this was not statistically different between the two groups.
CRF and HT also did not correlate with more significant
changes in serum NT-proBNP when examined separately.
Although the small patient numbers limit the statistical
reliability of our results, these findings would support the
hypothesis that inherent aberrant neurohumoral and cardio-
vascular alterations precede the development of ascites in
patients with advanced cirrhosis, and this is what places them
at risk of intravascular changes during LVP [15, 16].
Our findings of significant NT-proBNP changes at all
measured time points during LVP suggest that relative
intravascular depletion occurs relatively early during LVP
and even with small volumes of fluid removal (i.e., at 2-3 L).
The clinical significance of such changes may be questioned
given that they did not seem to correlate with any gross
changes in haemodynamic parameters nor in biochemistry
either at the end of drainage or at one week after paracentesis
(when PCD is most apparent). However, it is likely that the
liberal administration of albumin may have attenuated any
potentially significant clinical changes seen.
Although it remains somewhat controversial regarding
the issues of when, how, and how much colloid should be
administered during LVP, it has been recommended that
6–8 g/L of albumin should be administered following the
removal of volumes greater than 4-5 L in order to minimise
the risk of PCD [17, 18]. Albumin supplementation is often
recommended to begin following the end of drainage, when
the haemodynamic shifts are thought to begin. It was our
practice in the current study to administer 10 g/L of albumin,
beginning at 2 L and continued throughout the period of
drainage. Despite greater volumes of colloid, however, signif-
icant NT-proBNP changes were still seen to arise, particularly
among those patients with comorbid CCF.
Congestive cardiac failure was the only independent
predictor of significant NT-proBNP changes during LVP.
BaselineNT-proBNPvalueswere significantly higher in those
with concurrent CCF (2626.93 pg/mL versus 528.68 pg/mL),
and the mean decline in serum NT-proBNP during LVP was
approximately 50 times greater in those with concurrent CCF
than in those without (272.5 pg/mL versus 5.17 pg/mL). This
implies a potentially higher risk of haemodynamic compro-
mise and complications in these patients following LVP and
suggests that cirrhotic patients with CCF may benefit from
the earlier administration of greater volumes of supplemen-
tal albumin. Since NT-proBNP levels did not significantly
decline from the time of albumin administration through to
the end of drainage in all patient cohorts, this further vali-
dates the importance of colloid administration in abrogating
any significant fluid shifts during LVP.
Cirrhotic cardiomyopathy is an increasingly recognised
entity which refers to the impaired cardiac contractility, sys-
tolic and diastolic dysfunction, and electromechanical abnor-
malities that can develop in patients with advanced cirrhosis
[19, 20]. Its development can often be insidious, and it may
not always be apparent on routine clinical assessment. Serum
BNP and NT-proBNP are now recognised as valuable diag-
nostic andprognosticmarkers in the assessment of congestive
cardiac failure. Their utility in the diagnosis of cirrhotic
cardiomyopathy has also been examined.
Pimenta and colleagues [21] demonstrated that patients
with cardiac systolic dysfunction had higher baseline BNP
values than those of cirrhotic patients without a diagnosis
of heart failure. Similarly, Henriksen et al. [12] demonstrated
independent correlations of several important markers of
cardiac dysfunction (namely, greater QT interval, heart rate,
and plasma volume) with higher levels of proBNP and BNP
in cirrhotic patients not known to have CCF.They postulated
that raised BNP and proBNP levels could serve to identify
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Table 2: Clinical correlations with significant serum NT-proBNP changes at both time points.
2L prealbumin End of drainage
Clinical parameter 𝑃 value Clinical parameter 𝑃 value
Age 0.06 Age 0.12
Gender 0.98 Gender 0.98
Child-Pugh score 0.38 Child-Pugh score 0.84
MELD 0.06 MELD 0.05
Cause of cirrhosis: Cause of cirrhosis:
Alcohol versus nonalcohol 0.13 Alcohol versus nonalcohol 0.41
History of History of
Varices 0.18 Varices 0.37
Previous SBP 0.83 Previous SBP 0.89
Previous HE 0.80 Previous HE 0.57
HCC 0.68 HCC 0.87
Comorbid: Comorbid:
CCF 0.12 CCF 0.04
CRF 0.35 CRF 0.36
HT 0.87 HT 0.66
Diuretics 0.62 Diuretics 0.11
Serum Na 0.84 Serum Na 0.83
Serum creatinine 0.21 Serum creatinine 0.43
eGFR 0.22 eGFR 0.46
Serum bilirubin 0.60 Serum bilirubin 0.24
Serum albumin 0.32 Serum albumin 0.93
ALT 0.58 ALT 0.44
AST 0.78 AST 0.77
GGT 0.04 GGT 0.34
ALP 0.10 ALP 0.15
Haemoglobin 0.58 Haemoglobin 0.78
White cell count 0.07 White cell count 0.26
Platelets 0.13 Platelets 0.31
INR 0.12 INR 0.23
SAAG 0.05 SAAG 0.72
Ascitic protein 0.48 Ascitic protein 0.66
Ascitic albumin 0.47 Ascitic albumin 0.83
Baseline heart rate 0.56 Baseline heart rate 0.47
Baseline systolic BP 0.59 Baseline systolic BP 0.93
Baseline diastolic BP 0.59 Baseline diastolic BP 0.81
Total volume drained 0.79 Total volume drained 0.49
Baseline NT-proBNP <0.01 Baseline NT-proBNP 0.01
MELD: model for end-stage liver disease; HCC: hepatocellular carcinoma; CCF: congestive cardiac failure; CRF: chronic renal failure; HT: hypertension; Na:
sodium; eGFR: estimated glomerular filtration rate; ALT: alanine aminotransferase; AST: aspartate aminotransferase; GGT: gamma glutamate transferase; ALP:
alkaline phosphatase; INR: international normalised ratio; SAAG: serum ascites albumin gradient.

















All cirrhotics (𝑛 = 19) −77.27 pg/mL −94.29 pg/mL −17.0 pg/mL 0.67 3.7 L 185mls (37 grams)
Cirrhotics with concurrent
CCF/CRF/HT (𝑛 = 12) −88.63 pg/mL −130.34 pg/mL −41.7 pg/mL 0.32 4.1 L 205mls (41 grams)
All values are expressed as a mean (SEM).
CCF: congestive cardiac failure; CRF: chronic renal failure; HT: hypertension.
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early cardiac dysfunction in patients with cirrhosis. This
was seen in our cohort where significantly elevated NT-
proBNP levels were found in three cirrhotic patients in
whom a prior diagnosis of CCF had not been identified.
On retrospective analysis, these patients were indeed found
to have evidence of cardiac dysfunction on transthoracic
echocardiography,which had beenundertaken as part of clin-
ical assessments into unrelated disorders. Routine baseline
NT-proBNP measurements could therefore serve to detect
those cirrhotic patients with unrecognised cardiomyopathy,
as suggested by Sheer et al. [22], where serum NT-proBNP
levels > 1000 pg/mL reliably distinguished between ascites
due to CCF or cirrhosis.This would assist in the identification
of cirrhotic patients at greatest risk of PCD following LVP.
Due to the small sample size in this study, these results
should be interpreted with caution. This current analysis
should be regarded as a pilot study which could provide the
framework from which further trials could be undertaken in
order to better delineate the utility of NT-proBNP. In partic-
ular, whether significant NT-proBNP changes correlate with
more formal measures of PCD and longer-term outcomes
such as ascites recurrence andmortality, and whether routine
early administration of higher concentrations of supplemen-
tal albumin in cirrhotic patients with cardiac dysfunction can
improve clinical outcomes.
5. Conclusions
In summary, significant NT-proBNP changes during LVP
occur in patients with ascites secondary to cirrhosis but not
malignancy. Congestive cardiac failure was an independent
predictor of more significant NT-proBNP changes, further
supporting the utility of natriuretic peptides in the diagnosis
of cardiac dysfunction in patients with advanced cirrhosis,
hence their predictive potential in identifying those at great-
est risk of haemodynamic compromise and complications
following LVP.
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